BCL2 and cancer: Targeted therapies, such as ibrutinib and Venetoclax offer more specific approaches by targeting specific molecules involved in cancer cell growth, with ibrutinib inhibiting Bruton's Tyrosine Kinase (BTK), a key enzyme in B‐cell receptor signalling, and Venetoclax blocking BCL‐2, a protein that prevents apoptosis, thereby disrupting crucial survival pathways in cancer cells.